Form 4: Director Kenneth Alleyne Granted OneMedNet RSUs

OneMedNet Corp Director Kenneth Alleyne received a grant of 38,219 restricted stock units as compensation for his fiscal year 2025 board service.

Summary

• Kenneth Alleyne, a Director of OneMedNet Corp (ONMD), was granted 38,219 restricted stock units (RSUs).
• The RSUs were granted as compensation for his board service during fiscal year 2025 under the OneMedNet Corporation 2022 Equity Incentive Plan.
• Each RSU represents the contingent right to receive one share of OneMedNet's common stock.
• The RSUs are scheduled to vest on December 31, 2025, contingent upon Mr. Alleyne's continued service with the issuer through that date.
• The transaction date for this grant was November 26, 2025.

Sentiment

Score: 7

Explanation: Neutral to slightly positive. This is a routine compensation event, but equity grants generally align director interests with shareholders, which is a positive for governance and long-term company performance.

Positives

• The grant of 38,219 restricted stock units to a director aligns director incentives with long-term shareholder value.
• The compensation is part of the company's established 2022 Equity Incentive Plan, indicating a structured approach to executive and director compensation.

Risks

• The vesting of the 38,219 restricted stock units is subject to the reporting person's continued service with the issuer through December 31, 2025, meaning the shares are not guaranteed if service ceases before that date.

Future Outlook

The vesting of the granted restricted stock units on December 31, 2025, is contingent on Director Kenneth Alleyne's continued service, aligning future incentives with company performance and long-term strategic goals.

Industry Context

This is a standard director compensation practice within the healthcare technology sector, where equity grants are used to align the interests of board members with long-term shareholder value. Such grants are common across publicly traded companies to attract and retain qualified directors.

Comparison to Industry Standards

• Granting restricted stock units (RSUs) as director compensation is a common practice among publicly traded companies, including those in the healthcare technology sector like OneMedNet Corp, to incentivize long-term commitment and align director interests with shareholder value.
• The vesting schedule, tied to continued service, is typical for such equity awards, similar to practices seen at companies like Teladoc Health (TDOC) or Amwell (AMWL) for their non-employee directors.

Corporate Governance

Stakeholder Impact

• Shareholders: The grant of equity to a director aims to align their interests with long-term shareholder value, potentially leading to more shareholder-friendly decisions and improved governance.
• Employees: No direct impact on general employees is mentioned in this filing.

Next Steps

• Vesting of 38,219 restricted stock units on December 31, 2025, subject to continued service.

Key Dates

Recommendation

This Form 4 filing reports a routine grant of restricted stock units to a director as part of their compensation. While it aligns director incentives with shareholder interests, it does not present new information that would fundamentally alter the investment thesis for OneMedNet Corp, thus a 'hold' recommendation is appropriate based solely on this filing.

Keywords

OneMedNet Corp, ONMD, Form 4, SEC filing, Restricted Stock Units, RSUs, Director Compensation, Equity Incentive Plan, Insider Transaction, Kenneth Alleyne